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ABSTRACT
Despite optimal immunosuppressive therapy, more than 50% of kidney transplants fail because of
chronic allograft dysfunction. A noninvasive means to diagnose chronic allograft dysfunction may allow
earlier interventions that could improve graft half-life. In this proof-of-concept study, we used mass
spectrometry to analyze differences in the urinary polypeptide patterns of 32 patients with chronic
allograft dysfunction (14 with pure interstitial fibrosis and tubular atrophy and 18 with chronic active
antibody-mediated rejection) and 18 control subjects (eight stable recipients and 10 healthy control
subjects). Unsupervised hierarchical clustering showed good segregation of samples in groups corre-
sponding mainly to the four biomedical conditions. Moreover, the composition of the proteome of the
pure interstitial fibrosis and tubular atrophy group differed from that of the chronic active antibody-
mediated rejection group, and an independent validation set confirmed these results. The 14 protein
ions that best discriminated between these two groups correctly identified 100% of the patients with
pure interstitial fibrosis and tubular atrophy and 100% of the patients with chronic active antibody-
mediated rejection. In summary, this study establishes a pattern for two histologic lesions associated
with distinct graft outcomes and constitutes a first step to designing a specific, noninvasive diagnostic
tool for chronic allograft dysfunction.
J Am Soc Nephrol 20: 428–435, 2009. doi: 10.1681/ASN.2007101137
During the past three decades, the incidence and
prevalence of ESRD has increased each year all over
the world.1 Kidney transplantation is the treatment
of choice for ESRD because it prolongs survival,2
improves quality of life, and is less costly than dial-
ysis3; however, despite these improvements, a sub-
stantial proportion of grafts develop progressive
dysfunction and fail within a decade, even with the
use of appropriate dosages of immunosuppressive
drugs to prevent acute rejection.4 Chronic allograft
dysfunction (CAD) causes more than 50% of graft
losses.5–7 Although patients can return to dialysis
after transplant failure, loss of a functioning graft is
associated with a three-fold increase in the risk for
death,2,8,9 a substantial decrease in quality of life in
survivors, and a four-fold increase in cost.1,3
The decline in function, often associated with
hypertension and proteinuria, constitutes a clinical
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syndrome that has been called chronic allograft nephropathy
(CAN). The histopathologic hallmarks of these patients are
chronic interstitial fibrosis, tubular atrophy, vascular occlusive
changes, and glomerulosclerosis, usually evaluated by the
Banff working classification.10 Major outcomes discussed at
the last Banff Conference included the elimination of the non-
specific termCANand recognition of the entity “chronic active
antibody-mediated rejection” (CAAR).11 The rationale for this
update was the improper use of “CAN” as a generic term for all
causes of chronic renal allograft dysfunction with interstitial
fibrosis and tubular atrophy (IF/TA), which hampers accurate
diagnosis and appropriate therapy, and increasing recognition
of the role of alloantibody in chronic renal allograft deteriora-
tion and the corresponding histologic changes, making the
identification of an antibody-mediated component of chronic
rejection feasible.11
Effective strategies to prevent renal function deterioration
should focus on the early detection and treatment of patients
who develop CAD. In addition to elevated serum creatinine,
usually associated with proteinuria and arterial hypertension,
more specific and sensitive markers are needed to identify
high-risk patients or initial lesions without any changes in se-
rum creatinine or proteinuria.5,11
New analytic tools that allow rapid screening and accurate
protein identification in body fluids are now emerging within
the field of proteomic science. High-throughput mass spec-
trometry (MS) methods allow simultaneous detection of a
large number of proteins in a large set of biologic tissues or
samples. Protein fingerprinting MS methods using modern
matrix-assisted laser desorption/ionization-time of-flight MS
(MALDI-MS) instrumentation can detect hundreds of peak
signals that, as a whole, could be considered a reflex of the
body’s physiologic status.12 To date,MALDI-MS has been suc-
cessfully used to detect patterns of substantial overexpression
of proteins in cancer cells.13–15 Urine seems to be an ideal
source of potential biomarkers, and urine proteomic ap-
proaches have been used in numerous attempts to define bi-
omarkers for a variety of nephro-urologic disorders.16–18 The
aim of this study was to evaluate whether chromatography by
solid-phase extraction coupled to MS would differentiate uri-
nary polypeptide patterns in patients with pure IF/TA, patients
with CAAR, and two control groups: Healthy individuals and
stable renal transplant recipients.
RESULTS
Clinical and Histologic Characteristics of Patients with
CAD
The analysis included 50 individuals: 32 patients with CAD
(eight in training set and six in validation set with IF/TA with
no other cause and 10 in training set and eight in validation set
with CAAR) and 18 control subjects (10 healthy individuals
and eight stable renal transplant recipients). Table 1 shows the
baseline characteristic of patients with CAD and control sub-
jects.
Therewas no evidence ofCAARor transplant glomerulopa-
thy (TG), and C4d was negative in all patients with pure IF/TA
(G1). Mean glomerular double contour (CG) score was 1.89,
and C4d was positive in all patients in the CAAR group (G2).
Evidence of chronic active T cell–mediated rejection was ex-
cluded in all samples from this group. Table 2 summarizes
Banff scores in the IF/TA and CAAR groups. Table 3 shows the
HLAof both recipients and donors and the status of circulating
donor-specific anti-HLA antibodies in patients with CAAR
andwith the HLA analysis in the prebiopsy period. All patients
had available HLA matching data; none was HLA identical.
The mean HLA-A-B-DR mismatches was 4,16 (minimum 2,
maximum 6), and 100% of patients with CAAR had donor-
specific antibody (DSA) by FLOWPRA Specific Antibody De-
tection Test (One Lambda, Canoga Park, CA).
Urinary Proteome of Healthy Individuals Compared
with Those of Stable Transplant Recipients and
Patients with CAD
We found some differences between control subjects and pa-
tients withCAD. Patients withCAD (IF/TA andCAAR) always
had had peak clusters in three regions corresponding to mass/
charge (m/z) values of 2628 to 2922, 4307 to 4799, and 8303 to
8850, whereas the healthy urine protein profile had no peak
clusters in these m/z regions. All urine samples from healthy
individuals showed a peak m/z of 9754. Subsequently, an in-
formatics analysis was performed in a blind and systematic
manner as cases were added. (All data containing the peak
intensities and molecular weights in all patients are provided
online as supplemental information.)
Unsupervised hierarchical clustering using the 2000 pro-
teinswith the largest variability in thewhole set of spectrums in
Table 1. Clinical characteristic of study cohorts and controls groupsa
Characteristic
IF/TA Group
(n  14)
CAAR Group
(n  18)
Stable Renal
Transplant
Recipients
(n  8)
Healthy
Control
Subjects
(n  10)
Training Set
(n  8)
Validation Set
(n  6)
Training Set
(n  10)
Validation Set
(n  8)
Age (yr) 51.00  10.69 49.90  12.09 47.22  17.07b 51.00  15.20 36.20  8.00 43.00  10.00
Creatinine (mg/dl) 3.20  1.68 3.10  1.48 2.98  1.64b 2.80  0.82 1.08  0.30 0.91  0.30
Proteinuria (g/24 h) 2.67  2.90 2.63  2.70 3.11  3.33b 3.29  2.96 0.20  0.05 0.11  0.02
GFR (ml/min per 1.73 m2) 28.88  17.65 29.78  15.60 33.44  12.05b 27.90  10.10 82.22  4.00 110.00  10.00
aData are means  SD.
bT test NS between IF/TA and CAAR groups.
CLINICAL RESEARCHwww.jasn.org
J Am Soc Nephrol 20: 428–435, 2009 Proteomics in Graft Dysfunction 429
the m/z ranging from 1000 to 20000 showed good segregation
of samples in groups corresponding mainly to the four bio-
medical conditions: Healthy individuals and stable renal trans-
plant recipients (control groups) and patients with IF/TA and
CAAR (the two CAD groups; Figure 1). Note that some con-
founding occurred between some individuals with IF/TA and
CAAR and between some healthy individuals and individuals
with a stable renal transplant, a predictable result given the
slight clinical overlap between groups.
Differential Expression Analysis of Patients with CAD
In the unsupervised cluster analysis, patients with CAAR were
grouped together, separately from patients with IF/TA. These
results suggest that the composition of the urine proteome of
pure IF/TA is subtly different from that of the CAAR urine
proteome. Subsequently, we tried to determine the differences
in the urine proteomic profile among patients
with pure IF/TA and those with CAAR.
Differential expression analysis in a first set of
samples (training set) showed statistically signifi-
cant differences between the IF/TA and CAAR
groups; these differences identified possible bi-
omarkers that might confidently be used to dis-
tinguish between these two entities. Using the sig-
nificance analysis of microarrays (SAM)19
module in MeV,20 we reported 366 m/z values
with fold change (CAAR and IF/TA) 0.5 and a
significance of q 0.01 (q false discovery rate).
Mass proteins with fold change 0.5 in the m/z
range 2850 to 3050 are shown in Figure 2.
To validate protein signature obtained in the
training set, we considered an independent set of
samples (validation set) from IF/TA and CAAR
groups, equivalent to the training set. Unsuper-
vised clustering of the validation set using the 366
m/z obtained in the previous SAM analysis on the
training set shows very good segregation of this
new set in the two groups (Figure 3).
Furthermore, we analyzed the 366 selected
protein ions using discriminant analysis. The pro-
tein ions that best discriminated between the two
groups were 1529.22, 1529.45, 1539.8, 1540,03,
1541,87, 1542.1, 1574.79, 1575.02, 1575.25, 1575.48, 1575.72,
1587.86, 1657.4, and 6146.92, resulting in correct identifica-
tion of 100% (eight of eight) of the pure IF/TA group and
100% (10 of 10) of the CAAR group. Logistic regression (LR)
analysis resulted in selection of 1539.8, 1540.03, 1542.1,
1575.48, 1587.86, and 1657.4. A receiver operating character-
istic curve constructed from the logistic regression scores gave
a high area under the curve value of 1.0 (Figure 4). This distinct
protein signature is a suitable model for further identification
of biomarker candidates.
DISCUSSION
Like surface enhanced laser desorption/ionization technology,
direct polypeptide profiling by solid-phase extraction and
Table 2. Histopathology of allograft biopsiesa
Parameter
IF/TA Group CAAR Group
Training Set
(n  8)
Validation Set
(n  6)
Training Set
(n  10)
Validation Set
(n  8)
Glomerular double contours (cg) 0 0 1.89  0.70b 2.11  0.80
Interstitial fibrosis (ci) 1.88  0.90 1.95  0.60 2.11  0.70c 2.05  0.60
Tubular atrophy (ct) 1.88  0.90 1.95  0.60 2.11  0.70c 2.05  0.60
Arterial fibrous intimal thickening (cv) 0.88  0.60 1.10  1.00 1.56  1.00b 1.30  0.90
Hyaline arteriolar thickening (ah) 0.75  1.10 0.98  0.80 1.56  1.10c 1.10  1.20
Peritubular capillaritis (ptc) 0.75  0.40 1.10  0.50 1.33  0.70c 1.20  0.80
aData are means  SD.
bT test significant (P  0.05).
cT test NS.
Table 3. HLA of both recipients and donors and the status of
circulating donor-specific anti-HLA antibodies in patients with CAAR and
with the HLA analysis in the peribiopsy perioda
HLA Recipient HLA Donor DSA
A 3, 35. B 7, 18. DR 3, 7, 51 A 2, 31. B 7, 37. DR 3,7 A 2b
A 23, 29. B 8, 44. DR 1, 10 A 23. B 18, 58. DR 3, 10 B 18b
A 2. B 44, 60. DR 1,11 A 31. B 44, 60. DR 3,11 A 31b
A 2, 23. B 35, 44. DR 4, 7, 53 A 2, 23. B 44, 60. DR 7, 13 A 23
A 1, 25. B18. DR 103 A 26, 34. B 14. DR 1–15 A 26
A 24, 30. B 18, 62. DR 17,4,52 A 2, 32. B 7, 60. DR 1, 11 A 2
A 1, 3. B 8, 27. DRb1 4, 13 A 29, 68. B 8, 13. DRb1 4, 13 B 13
A 1, 9. B 44, 55. DR 7, 8 A 2, 29. B13, 18. DR 1, 3 A 2
A 1, 3. B 7, 38. DRb1 1, 10 A 24, 31. B 39, 45. DR 4–10 A 31
A 2, 23. B 7, 44. DRb1 15, 13 A 2, B 7, 44. DR 13, 15 B 44
A 1, 26. B 8, 35. DRb1 13, 14 A 1, 3. B 8, 35. DR 3, 4 B 8
A 2, 29. B 7, 44. DRb1 7, 15 A 3, 29. B 7, 44. DR 2 B 44
A 2, 24. B 18, 44. DRb1 4, 11 A 3, 28. B 7, 18. DR 15, 11 B 18
A 1, 3. B 8, 27. DRb1 3, 10 A 3, 80. B 8, 58. DR 3, 8 A 3b
A 23, 31. B 51, 44. DR 5, 7 A 23, 30. B 42, 49. DR 11, 17 B 42b
A 2. B 44, 60. DR 1, 6, 52 A 2, 28. B 35, 49. DR 1, 3 A 28b
A 2, B 44, 62. DRb1 11, 13 A 1, 3. B 35, 37. DR 7. B 35b
A 2, 24. B 8. DR 3, 11 A 2. B 45. DR 3, 11 A 2b
aThe cases with positive panel-reactive antibodies were tested for HLA antibody specificities
using FlowPRA Specific Antibody Detection Test (One Lambda).
bPatients with CAAR from independent validation set.
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MALDI-MS reduces the complexity of a sample by selective
adsorption of proteins to an active surface and is a relatively
simple proteomic approach that allows rapid differential diag-
nosis of patients and information transfer between the labora-
tory and the clinical context.18 The processes that result in
CAD are poorly understood. Although determination of organ
failure often relies on measurable physiologic parameters, the
early stages of CAD are difficult to diagnose. Detection re-
quires invasive procedures to obtain graft biopsies for histo-
logic evaluation.5 To our knowledge, this is the first prelimi-
nary report on this broad-based, unbiased, noninvasive
proteomic and bioinformatics approach as ameans to design a
noninvasive diagnostic tool for CAD.
The large quantity of protein data generated requires com-
plementary bioinformatics tools to identify differential pat-
terns of value, and a mathematical model was used to distin-
guish between the overlapping sets of results.21,22 To avoid
biases and misinterpretation between the
CAAR and IF/TA groups, the samples ana-
lyzed were taken from patients with similar
follow-up after transplantation, the same
immunosuppressive treatment, similar re-
nal function, and similar Banff score on IF/
TA. The only difference between the two
groupswas the presence of histologicmark-
ers of CAAR and HLA DSA in the CAAR
group. Allergic drug reactions, systemic or
intragraft infections, and other inflamma-
tory processes were reasonably excluded.
Initially, comparative bioinformatics
urine proteomic analysis detected differ-
ences among healthy individuals, stable
transplant recipients, and patients with
IF/TA and CAAR, showing an excellent
clinical correlation. Importantly, the pres-
ence of IF/TA is another criterion required
for a diagnosis of CAAR, and the absence of
differences in the IF/TA scores of the two
groups is a plausible explanation for the
finding that both groups (two CAAR sam-
ples were interchangeable with two IF/TA
samples) share somemass values. The same
phenomenon occurred in two stable renal
transplant samples and two samples from
healthy individuals, indicating that these
groups have some urine proteins in com-
mon.
When we analyzed our two groups of
patients with CAD in greater detail, the dif-
ferential expression analysis confirmed dif-
ferences between patients with pure IF/TA
and patients with IF/TA plus CAAR. The
mass range analysis highlighted these dif-
ferences, whereas comparison with tradi-
tional markers (creatinine and protein-
uria)5,11 of CAD demonstrated that our markers had
discriminatory power. Moreover, the independent and equiv-
alent validation set confirms the results from the training set.
The presence of IF/TA in protocol renal allograft biopsies is
an independent predictor of graft survival.23,24 Recently, IF/TA
associated with transplant vasculopathy,25 subclinical rejec-
tion, and TG was shown to be associated with a poorer out-
come and prognosis than IF/TA without additional lesions
(pure IF/TA).26,27 Although histologic lesions predict graft sur-
vival, their accuracy has been poorly characterized. Prelimi-
nary data suggest that their predictive value in graft survival is
at least not inferior to that of acute rejection or renal function.
In addition, quantitative evaluation of histologic lesions has
been performed in an attempt to provide a better surrogate
marker for graft half-life. Both morphometry and image anal-
ysis have been used to quantify interstitial fibrosis and trans-
plant vasculopathy, but neither of these parameters has been
Figure 1. (A) Detail of unsupervised hierarchical clustering using the 2000 m/z
features with the largest variability in the entire set of samples (HCL* module of MeV
package).24 (B) Matrix representation of the distances (inverse of the similarity) be-
tween samples, using the same features as those used in A (GDM module of MeV
package).
CLINICAL RESEARCHwww.jasn.org
J Am Soc Nephrol 20: 428–435, 2009 Proteomics in Graft Dysfunction 431
properly validated. An alternative strategy to increase the pre-
dictive value of protocol biopsies in graft outcome was valida-
tion with composite end points containing histologic, clinical,
biologic, and analytical parameters.28
This study reveals a differential link between specific clinical
factors, histologic findings, and urine proteome among pa-
tients with CAAR and those with IF/TA without additional
lesions. Despite the limited number of patients analyzed, the
unsupervised cluster analysis differentiated between patients
with pure IF/TA and those with CAAR (IF/TACAAR), sup-
porting the importance of the recent update of the Banff work-
ing classification of CAD.
In view of the complex relationship among clinical and bi-
ologic CAD factors and among early histopathologic changes
and graft outcome, the search for a urine biomarker panel to
identify the various causes of CAD seems absolutely necessary
to improve long-term graft survival. Moreover, the different
urine protein excretion patterns in patients with pure IF/TA
versus those with CAAR detected in this study will support the
identification of different urine biomarkers for these two his-
tologic lesions with distinct outcomes; notably, the CAD pat-
tern had peak clusters in three regions with high linkage, which
could be used in investigation of urinary markers of graft fi-
brosis. The combination of protocol graft biopsies with simul-
taneous proteomic analyses at different times after renal trans-
plantation could provide more accurate information on the
exact mechanisms involved in the development of CAD. This
information could be very helpful not only for an early diag-
nosis of CAD but also in the treatment and prevention of the
leading cause of graft loss.
Additional studies including a larger and more diverse
transplant recipient population are required to confirm our
data. Reproduction of these patterns in future studies would
represent a step forward in identifying each protein and in
translating this relatively intricate procedure into a biochemi-
cal test of clinical utility.
CONCISE METHODS
Study Cohorts
Fifty individuals were included in the study: 32 patients with clinical
and histopathologic characterization of CAD and 18 control subjects.
The patients were divided in two groups: (1) 14 patients (nine men
and five women) with IF/TA and no evidence of any specific cause
(IF/TA group) and (2) 18 patients (12 men and six women) with
CAAR defined bymorphologic features including TG and IF/TAwith
or without peritubular capillary loss, and fibrous intimal thickening
in arteries without duplication of the internal elastica, diffuse C4d
Figure 2. Distribution of fold change in the m/z range 2850 to
3050. Significant underexpressed features in the range of 2850 to
3050 m/z showing a mean value (CAAR) group/mean value (IF/TA
group) 0.5. This condition normally adds biologic relevance to
statistical results.
Figure 3. Detail of unsupervised hierarchical clustering on the
new validation samples, using the 366 features statistically differ-
entiated in the SAM19 analysis on training samples (HCL* module
of Mev Package).24
Figure 4. Receiver operating characteristic (ROC) curve for
1539.8, 1540.03, 1542.1, 1575.48, 1587.86, and 1657.4 protein
ions were generated using logistic regression scores, with an area
under the curve of 1.0.
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deposition in peritubular capillaries (PTC), and the presence of DSA
(CAAR group).
All transplant recipients received immunosuppressive treatment
with a calcineurin inhibitor, mycophenolate mofetil, and prednisone.
There were no significant differences between the IF/TA and CAAR
groups with respect to age, gender, diabetes duration, arterial BP,
body mass index, and GFR (Table 1).
The control subjects were divided in two groups: (1) Stable renal
transplant recipients, who were eight live-donor recipients of a first
renal graft at the end of the first month after surgery with normal
pretransplantation biopsy and after immunosuppressive treatment
with tacrolimus, mycophenolate mofetil, and prednisone (mean age
36.2  8.0, mean serum creatinine 1.08  0.30 mg/dl, and mean
proteinuria 205.2 50.0 mg/d) and (2) healthy control subjects, who
were 10 volunteers with normal BP (systolic BP 130 mmHg and
diastolic BP 80 mmHg) and no history of diabetes, ischemic heart
disease, stroke, or peripheral vascular disease (mean age 43  10 yr;
sevenmen and threewomen,mean creatinine 0.91 0.30mg/dl, GFR
110  10 ml/min, mean microalbuminuria/creatinuria 4  1 mg/g,
mean proteinuria/creatinuria 39 6 mg/g). The study was approved
by the institutional review board at the Hospital Clinic in Barcelona,
and both patients and control subjects gave informed consent for the
collection and analysis of their urine.
Histopathology
Transplant biopsies consisted of two cores obtained with 18-gauge
needles using ultrasound guidance because of clinical indication. Par-
affin sections were prepared and stained with hematoxylin-eosin,
trichrome, periodic acid-Schiff, and periodic acid-Schiff–methena-
mine silver.
The biopsies were analyzed andwere scored according to the Banff
classification by a pathologist who was blinded to the results of mo-
lecular studies.10,29 TGwas diagnosed by lightmicroscopy on the basis
of double contours of glomerular basement membranes10 and was
supported by immunofluorescence studies, which showed mesangial
IgM and/or C3 or negative immunofluorescence findings. Peritubu-
lar capillaritis in TG biopsies was graded according to the quantitative
criteria of the last Banff update.11 C4d stainingwas done in all biopsies
using frozen tissue. Murine monoclonal anti-human C4d 100 lL
(Quidel Corp., San Diego, CA), followed by fluorescence antisera
(CyTM2-conjugated AffiniPure Goat Antimouse IgG; Jackson Im-
munoResearch Laboratories, West Grove, PA) were added to the fro-
zen sections. Linear staining of PTC for C4d with mild intensity or
above was graded as diffuse (estimated50% of sampled capillaries)
or focal (1 to 50% of sampled capillaries) positive.30 Biopsies from
patients with previously documented diffuse positive C4d in PTC
served as positive controls.
Anti-HLA Antibody Analysis
Recipient sera taken in the prebiopsy period were screened for HLA
class I and class II antibodies by FlowPRA. When positive, antibody
specificitieswere determined by FlowPRASpecific class I and or II and
or FlowPRA Single Antigen I and II beads (One Lambda). Beads were
analyzed on a BD FACSCalibur cytometer. Antibody specificities to
HLA-A, B, DRb1, DRb3, DRb4, DRb5, DQb1 were evaluated.
Sample Preparation and Purification
Fifty milliliters of early morning urine was collected immediately be-
fore renal biopsy, adding protease inhibitor cocktail (CompleteMini;
Roche, Mannheim, Germany); rapidly frozen in dry ice; and stored at
80°C until analyzed. Urine samples were concentrated and sepa-
rated from organic salts by solid-phase extraction using a reverse-
phaseHLBOasis 94226 (Waters,Milford,MA) as the stationary phase
and according to the following protocol: Conditioning in 10 ml of
100% acetonitrile (ACN), equilibration in 10ml of 0.1% trifluoroace-
tic acid (TFA)/5% ACN, loading of sample (acidified with 0.1% TFA
at pH3 and final concentration of 5%ACN),washingwith 10ml 0.1%
TFA/5% CAN, and elution with 2 ml of 0.1% TFA/60% ACN.
Each sample was applied and dried on an uncoatedMALDI target
plate using the sandwich technique (1 l of sample plus 2 l of ma-
trix). A saturated solution of 3,5-dimethoxy-4-hydroxycinnamic acid
(sinapinic acid; Sigma, St. Louis, MO) in ACN/H2O/TFA 50/50/0.3
was used asmatrix. Ten spots were prepared and analyzed per sample.
Mass Spectrometer Data Acquisition
Mass spectra were acquired with a Voyager-DE PRO TM Biospec-
trometry Workstation (Applied Biosystems, Foster City, CA), and
data were obtained by using the linear acquisition mode under de-
layed extraction conditions. Instrument settings were an accelerating
voltage of 25 kV, 91% grid voltage, 0.05% guidewire voltage, delay
time of 220 ns, and bin size of 2 ns. Three spectra (three acquisitions of
150 shots each) were acquired for each replicate. Internal calibration
standards were insulin bovine 0.5 pmol/l, thioredoxin from Esche-
richia coli 2.75 pmol/l, and apomyoglobin from horse 4 pmol/l
(standard mixture 3 from Applied Biosystems). Deposition of the
samples on the MALDI target and mass spectra acquisition were per-
formed randomly.
Data Analysis
Baseline Correction.
The chemical noise present in each spectrum was estimated by deter-
mining the minimal measured intensity value in successive 100 m/z
windows. A function fit to these minima by least squares was defined
as baseline and subtracted from the spectrum.
Binning of Peaks.
Data were analyzed for the molecular weight range of 1.0 to 20 kD.
The three spectra from each replicate were averaged arithmetically,
and automated peak detectionwas carried out on these averaged spec-
tra in Data Explorer 4.3 software, which determines the centroid
mass, height for the 50th percentile of the lower and upper boundary
of the peak, and area and signal-to-noise ratio for each peak (signal-
to-noise threshold of 2, a 5-kD for computing noise and 50% centroid
to define peak width).
Preprocessing of MS Data
For the comparison of the peaks included in different spectra, peak
alignment was performed with an agglomerative hierarchical cluster-
ing algorithm.21 The algorithm initially creates as many clusters as
detected peaks in all spectra and successively merges the closest clus-
ters if all of the peaks of the new cluster belong to different spectra and
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the maximal mass distance between two peaks of the new cluster is
0.2% of their mean. This tolerance corresponds to a measurement
error of 0.1%.22
Bioinformatics and Statistical Analysis
Unsupervised bidimensional cluster analysis of features showingwide
variability was performed and displayed using theMeVpackage in the
TM4 software suite.20
Statistical differential analysis was performed for the signal inten-
sities of the peaks detected. The SAM method was used to identify
significant differentially expressed features while controlling for the
false discovery rate.19
In high-throughput experiments, large number of features may
display changewith ordinary levels of significance (i.e.,P 0.05) even
when no biologic differences exist. One approach to surmount this
problem inmultiple comparisons is to identify the false discovery rate
(q value). A valuable feature of SAM analysis is that it gives estimates
of the false discovery rate, which is the proportion of features likely to
have been identified by chance as being significant.
The protein ions were then analyzed using discriminant analysis
(Systat 10.2; Richmond, CA) to identify combinations of proteins that
best discriminate between disease states. A logistic regression model
was also built using the same protein ions to calculate prediction
scores for each sample, allowing us to construct a receiver operating
characteristic curve based on these values.31
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